OS Therapies (OSTX)
NYSE: OSTX
· Real-Time Price · USD
2.34
-0.16 (-6.40%)
At close: Aug 28, 2025, 10:30 AM
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OS Therapies
| Country | United States |
| IPO Date | Aug 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Paul A. Romness |
Contact Details
Address: 15825 Shady Grove Road Suite 135 Rockville, Maryland United States | |
| Website | https://ostherapies.com |
Stock Details
| Ticker Symbol | OSTX |
| Exchange | NYSE |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001795091 |
| CUSIP Number | n/a |
| ISIN Number | US68764Y2072 |
| Employer ID | 82-5118368 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul A. Romness M.P.H. | Founder, Chairman, President & Chief Executive Officer |
| Christopher P. Acevedo | Chief Financial Officer |
| Dr. Robert G. Petit Ph.D. | Chief Medical Officer & Chief Scientific Officer |
| Gerald E. Commissiong | Chief Business Officer |
| Jack Doll | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2025 | 8-K | Current Report |
| Aug 26, 2025 | ARS | Filing |
| Aug 25, 2025 | DEFA14A | Filing |
| Aug 25, 2025 | DEF 14A | Filing |
| Aug 25, 2025 | 424B5 | Filing |
| Aug 25, 2025 | 424B3 | Filing |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 18, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Aug 18, 2025 | 10-Q | Quarterly Report |
| Aug 15, 2025 | PRE 14A | Filing |